SubHero Banner
Text

January 2024

Core topics in this month’s edition include:

  • Balversa (erdafitinib) – updated indication; full FDA approval 
  • Glucagon-like peptide-1 receptor agonists safety update
  • Zelsuvmi (berdazimer) - new drug approval

Download PDF

Text